Warm Springs Advisors Inc. Sells 991 Shares of Boston Scientific Corporation $BSX

Warm Springs Advisors Inc. cut its position in shares of Boston Scientific Corporation (NYSE:BSX) by 13.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,635 shares of the medical equipment provider’s stock after selling 991 shares during the quarter. Warm Springs Advisors Inc.’s holdings in Boston Scientific were worth $713,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. 1248 Management LLC bought a new position in shares of Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd purchased a new position in Boston Scientific in the first quarter worth $27,000. Sound Income Strategies LLC grew its stake in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Princeton Global Asset Management LLC bought a new position in Boston Scientific in the 2nd quarter valued at $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at $37,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 175,782 shares of company stock worth $17,742,314 over the last quarter. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Robert W. Baird boosted their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Barclays boosted their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Stock Performance

NYSE:BSX opened at $99.00 on Friday. The business’s fifty day moving average is $100.20 and its 200 day moving average is $102.40. The firm has a market cap of $146.69 billion, a price-to-earnings ratio of 52.94, a PEG ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the firm earned $0.63 EPS. The company’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.